Tirzepatide is a dual GIP/GLP-1 receptor agonist peptide, sold as Mounjaro (for diabetes) and Zepbound (for weight management). It targets both incretin receptors simultaneously, distinguishing it from GLP-1-only drugs like semaglutide.

How much weight can you lose on tirzepatide?

Clinical trials show 15-22.5% body weight reduction at the 15mg dose over 72 weeks. In head-to-head trials, tirzepatide achieved greater weight loss than semaglutide 2.4mg.

Is tirzepatide better than semaglutide?

Tirzepatide produces greater weight loss and comparable or better glycaemic control in head-to-head trials. However, it has a higher GI adverse event rate, though paradoxically lower discontinuation rates. The choice depends on individual tolerance and treatment goals.

What is biased agonism in tirzepatide?

Tirzepatide is engineered to prioritise cAMP signalling while avoiding beta-arrestin recruitment at the GLP-1 receptor. This prevents receptor shutdown, enabling prolonged signalling that natural hormones cannot achieve.

Does tirzepatide cause muscle loss?

Approximately 25% of total weight lost on tirzepatide is lean mass. Real-world data suggests the absolute lean mass loss may exceed that seen with semaglutide. A structured resistance training and high-protein diet protocol is considered standard of care.

Does tirzepatide affect bone density?

Clinical data shows 2.1-2.6% bone mineral density loss at the hip and spine over 52 weeks. Calcium and vitamin D supplementation alongside resistance training are recommended.

What is the tirzepatide dosing schedule?

Start at 2.5mg weekly for 4 weeks, then increase by 2.5mg every 4 weeks. Maintenance dose is individualised at 5mg, 10mg, or 15mg based on response and tolerance.

Is tirzepatide approved for sleep apnoea?

Yes. Tirzepatide received FDA approval for moderate-to-severe obstructive sleep apnoea in adults with obesity, based on the SURMOUNT-OSA trial showing AHI reductions of 20-24 events per hour.

Tirzepatide: Dual GIP/GLP-1 Peptide Profile

Tirzepatide is a synthetic 39-amino-acid peptide acting as a unimolecular dual agonist of GIP and GLP-1 receptors, engineered with a 5:1 functional bias toward the GIP receptor.

Biased Agonism at GLP-1R

The defining feature of tirzepatide's GLP-1 receptor interaction is biased agonism. It prioritises cAMP production while avoiding beta-arrestin recruitment. Beta-arrestin normally signals the receptor to internalise and shut down. By sidestepping this pathway, tirzepatide prevents receptor desensitisation, allowing prolonged signalling that natural hormones cannot achieve.

Four Parallel Cascades

Glucose-dependent insulin secretion: Stimulates pancreatic beta-cells only when blood glucose is elevated, minimising hypoglycaemia risk.
Glucagon suppression: Reduces hepatic glucose output by inhibiting alpha-cell glucagon release.
Delayed gastric emptying: Slows nutrient transit, reducing postprandial glucose spikes and contributing to satiety.
Central appetite regulation: Acts on hypothalamic receptors to reduce hunger signalling.

The GIP Receptor Component

The GIP receptor arm drives adipose tissue remodelling, may buffer GI nausea signals, and supports bone metabolism. This dual-receptor architecture is what separates tirzepatide from GLP-1-only drugs.

Tirzepatide is administered as a once-weekly subcutaneous injection. A C20 fatty diacid modification enables albumin binding, extending the half-life to approximately 5 days (114-120 hours).

Weight Reduction

Tirzepatide delivers the largest weight reductions recorded in incretin-class trials:

SURMOUNT-1 (N=2,539): 15-22.5% body weight reduction at 72 weeks depending on dose (5 mg, 10 mg, or 15 mg).
SURMOUNT-2 (N=938): 15.7% weight loss at the 15 mg dose over 72 weeks in patients with type 2 diabetes.
SURMOUNT-5 (head-to-head): Tirzepatide achieved greater weight loss than semaglutide 2.4 mg in a direct comparison trial.

Glycaemic Control

The SURPASS programme demonstrated HbA1c reductions of 1.9-2.6%, with 23-52% of participants achieving normoglycaemia (HbA1c <5.7%). These glycaemic results exceed those seen with any single-agonist GLP-1 drug.

Diabetes Prevention

SURMOUNT-1 extension data showed sustained weight loss and markedly lower progression to type 2 diabetes over 3 years, positioning tirzepatide as a potential prevention tool, not only a treatment.

Metabolic Syndrome Reversal

Across the SURPASS programme, tirzepatide produced significant reductions in the prevalence of metabolic syndrome criteria, reflecting broad metabolic restoration beyond isolated glucose or weight endpoints.

Heart Failure (HFpEF)

The SUMMIT trial (N=731) showed a 38% reduction in the composite of cardiovascular death or worsening heart failure over 104 weeks in patients with HFpEF and obesity. This is the strongest heart failure signal in the incretin class.

Cardiovascular Outcomes

SURPASS-CVOT: Established non-inferiority to dulaglutide for major adverse cardiovascular events (MACE). A 16% reduction in all-cause mortality was observed, driven primarily by non-cardiovascular deaths. The trial did NOT establish statistical superiority for the primary 3-point MACE endpoint.
Blood pressure: Systolic reductions of 2.8 to 12.6 mmHg across SURPASS trials, consistent with weight-dependent haemodynamic improvement.

Renal Protection

SURPASS-4 slowed annual eGFR decline by 2.2 mL/min versus insulin glargine and produced a 31.9% reduction in urinary albumin-to-creatinine ratio (UACR). The renal benefit was most pronounced in patients with eGFR below 60 mL/min.

Sleep Apnoea (OSA)

Tirzepatide holds an FDA-approved indication for moderate-to-severe obstructive sleep apnoea in adults with obesity. The SURMOUNT-OSA trial demonstrated AHI reductions of 20-23.8 events per hour alongside significant reductions in hypoxia burden.

All CNS data for tirzepatide is preclinical. No human neurological trials have been completed. The following findings come from animal models and should not inform treatment decisions.

Alzheimer's and the 'Type 3 Diabetes' Hypothesis

Tirzepatide crosses the blood-brain barrier and restores brain insulin sensitivity via the PI3K/AKT/GSK3-beta pathway. In rodent models, it attenuates neuroinflammation by suppressing the NLRP3 inflammasome and NF-kB pathways.

Cellular Clearance

Autophagy restoration: Tirzepatide upregulates cellular autophagy, helping clear amyloid-beta plaques in certain animal models.
Glucose transporter upregulation: Increases expression of GLUT1 and GLUT3 in brain tissue, improving neuronal glucose uptake.

Conflicting Evidence

One study found that tirzepatide did NOT reduce amyloid plaque burden in specific transgenic mouse models, highlighting that preclinical results are inconsistent and far from settled.

Lean Mass Loss

The SURMOUNT-1 DXA substudy shows that approximately 25% of total weight lost on tirzepatide is lean mass. While this ratio is better than semaglutide's 40%, real-world electronic health record data from the nSights network reveals significantly higher absolute lean mass loss with tirzepatide than with semaglutide, likely driven by the larger total weight reduction.

Bone Density

Clinical data shows 2.1-2.6% bone mineral density (BMD) loss at the hip and spine over 52 weeks. This is roughly double the annual rate seen in untreated post-menopausal women. A Weill Cornell retrospective analysis confirms that BMD decline correlates with the magnitude of weight loss.

The underlying mechanism is an uncoupling of bone turnover: resorption markers increase, but formation markers do not compensate. This creates a net bone deficit that accumulates with continued therapy.

The Burnham Protection Protocol

Dr Jeremy Burnham's musculoskeletal protection protocol has emerged as the standard of care for patients on incretin therapy:

Resistance training: 3 sessions per week, structured for progressive overload.
Protein intake: 1.2-1.6 g/kg body weight per day.
Calcium: 1,000-1,200 mg daily.
Vitamin D3: 1,500-2,000 IU daily.

Natural incretins (GIP and GLP-1) are full agonists at both receptors. Tirzepatide is engineered differently.

Receptor-Specific Behaviour

At the GIP receptor: Full agonist with 5:1 potency bias. Tirzepatide activates GIP signalling with higher affinity than its GLP-1 activity.
At the GLP-1 receptor: Biased partial agonist. A modified N-terminal sequence changes how the cell responds to receptor activation.

The cAMP / Beta-Arrestin Split

Tirzepatide favours cAMP production (which drives the metabolic benefits) while avoiding beta-arrestin recruitment. Beta-arrestin normally tells the receptor to internalise and shut down. By bypassing this signal, tirzepatide prevents receptor desensitisation, enabling prolonged and potent signalling from each receptor binding event.

This molecular engineering explains why tirzepatide outperforms previous-generation metabolic drugs that rely on balanced agonism.

The Antagonism Debate

An active debate exists about whether GIP receptor antagonism (blocking, rather than activating) may be superior for weight loss. Amgen's MariTide (AMG 133) takes this opposite approach, combining GLP-1 agonism with GIP receptor antagonism. Early data is promising but immature. The field has not yet settled whether maximal GIP activation or GIP blockade is the better metabolic strategy.

Tirzepatide moves metabolic treatment past the era of single-target drugs. The scale dropping is the most visible symptom of a deeper, cellular restoration. But the speed of that restoration demands that clinicians prescribe the protection plan alongside the peptide.

1.Mechanism of Action

Biased Agonism at GLP-1R

Four Parallel Cascades

The GIP Receptor Component

Explore This Protocol

Safety Triggers

Research Gaps

Contrarian Views

Protocol Reference

Related Research

Blood Sugar Regulation

Insulin Sensitivity

Semaglutide

Appetite Suppression

Neuroprotection

Cardiovascular Health

Stay Ahead of the Research

2.Weight Loss and Metabolic Outcomes